Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. Atara ...

A couple of months after Thousand Oaks-based Atara Biotherapeutics announced it would be laying off roughly 80 employees, the company confirmed nearly half of those jobs are coming from its Ventura ...

--(BUSINESS WIRE)--Atara Biotherapeutics ... “We will further narrow our focus on the future financial value of EBVALLO for the benefit of all stakeholders. Atara continues to productively ...

and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Atara Biotherapeutics to post ...

ATRA opened at $6.91 on Wednesday. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $23.44. The stock has a market cap of $39.80 million, a P/E ratio of -0.27 and a beta of ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report) yesterday and set a price ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

THOUSAND OAKS, Calif., February 07, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...